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The inhibition of FGF receptor 1 activity
mediates sorafenib antiproliferative effects
in human malignant pleural mesothelioma
tumor-initiating cells
Alessandra Pattarozzi1, Elisa Carra2, Roberto E. Favoni2, Roberto Würth1, Daniela Marubbi2,3, Rosa Angela Filiberti3,
Luciano Mutti4, Tullio Florio1*† , Federica Barbieri1*† and Antonio Daga3†
Abstract
Background: Malignant pleural mesothelioma is an aggressive cancer, characterized by rapid progression and high
mortality. Persistence of tumor-initiating cells (TICs, or cancer stem cells) after cytotoxic drug treatment is responsible for
tumor relapse, and represents one of the main reasons for the poor prognosis of mesothelioma. In fact, identification
of the molecules affecting TIC viability is still a significant challenge.
Methods: TIC-enriched cultures were obtained from 10 human malignant pleural mesotheliomas and cultured in vitro.
Three fully characterized tumorigenic cultures, named MM1, MM3, and MM4, were selected and used to assess
antiproliferative effects of the multi-kinase inhibitor sorafenib. Cell viability was investigated by MTT assay, and cell
cycle analysis as well as induction of apoptosis were determined by flow cytometry. Western blotting was performed to
reveal the modulation of protein expression and the phosphorylation status of pathways associated with sorafenib
treatment.
Results: We analyzed the molecular mechanisms of the antiproliferative effects of sorafenib in mesothelioma TIC cultures.
Sorafenib inhibited cell cycle progression in all cultures, but only in MM3 and MM4 cells was this effect associated with
Mcl-1-dependent apoptosis. To investigate the mechanisms of sorafenib-mediated antiproliferative activity, TICs were
treated with epidermal growth factor (EGF) or basic fibroblast growth factor (bFGF) causing, in MM3 and MM4 cells, MEK,
ERK1/2, Akt, and STAT3 phosphorylation. These effects were abolished by sorafenib only in bFGF-treated cells, while a
modest inhibition occurred after EGF stimulation, suggesting that sorafenib effects are mainly due to FGF receptor
(FGFR) inhibition. Indeed, FGFR1 phosphorylation was inhibited by sorafenib.
Moreover, in MM1 cells, which release high levels of bFGF and showed autocrine activation of FGFR1 and
constitutive phosphorylation/activation of MEK-ERK1/2, sorafenib induced a more effective antiproliferative
response, confirming that the main target of the drug is the inhibition of FGFR1 activity.
Conclusions: These results suggest that, in malignant pleural mesothelioma TICs, bFGF signaling is the main target of
the antiproliferative response of sorafenib, acting directly on the FGFR1 activation. Patients with constitutive FGFR1
activation via an autocrine loop may be more sensitive to sorafenib treatment and the analysis of this possibility
warrants further clinical investigation.
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Background
Malignant pleural mesothelioma (MPM) is an aggressive
and heterogeneous cancer that, after transient response
to first-line treatments, relapses rapidly [1]. MPM still
has a poor prognosis, with a median survival of 9–17
months, only slightly improved by the introduction of
folate inhibitor/cisplatin combination chemotherapy [2].
Ongoing clinical trials are expected to provide informa-
tion about the efficacy of the association of standard
treatment with new targeted molecules [3].
The evolving theory of cancer stem cells (CSCs) postu-
lates that the capacity to drive tumor formation and
growth resides in a subpopulation of tumor cells, namely
CSCs or tumor-initiating cells (TICs) [4]. CSCs are able to
self-renew, differentiate into heterogeneous nontumori-
genic cancer cells forming the bulk of tumor mass, and
develop tumors in murine models. These cells also possess
intrinsic chemoresistance and radioresistance and act as a
reservoir of cancer cells responsible for relapse after
surgery, radiation, or chemotherapy [5]. CSCs, identified
in many human solid cancers including MPM, are mech-
anistically responsible for treatment failure, tumor relapse,
and metastasis development [5]. Thus, the identification
of CSC-targeting drugs represents a translationally rele-
vant approach to improve cancer therapy [6], in particular
to overcome refractoriness to conventional anticancer
agents.
Preclinical CSC-based models, suitable to study the
mechanisms by which novel drugs target tumor cells, are
much less developed in MPM than in other solid tumors
[6]. Candidate MPM CSCs were mostly derived from
established human cell lines [7–9] and only few studies
described the isolation of CSCs from primary cultures of
human MPM cells [10, 11].
Several preclinical studies reported significant results in
MPM using tyrosine kinase inhibitors (TKIs), targeting
overexpressed and/or autocrinally activated growth factor
receptors [12–14]. Unfortunately, most of them failed to
achieve the expected survival benefits when translated into
the clinical setting [15], possibly because MPM growth is
sustained by deregulation of several receptor tyrosine ki-
nases (RTKs), and the inhibition of a single pathway is in-
sufficient to give clinical benefits. Moreover, substantial
evidence validates the cross-talk among RTKs, including
epidermal growth factor (EGF), basic fibroblast growth fac-
tor (bFGF), vascular endothelial growth factor (VEGF), and
platelet-derived growth factor (PDGF) receptors, and their
aberrant signaling in cancer. Thus, the use of drug combi-
nations or multi-targeted agents acting on several RTKs
and/or cytosolic kinases along downstream pathways, offers
a more promising approach for the treatment of MPM. In-
vestigations on the molecular pathogenesis of MPM
highlighted signal transduction dysregulation in key path-
ways connecting RTKs and MAPK cascade. Consistently,
dual targeting of TKs and signaling pathways in MPM pa-
tients represents a promising treatment option [3].
In this article, we investigated the antiproliferative
effect of sorafenib, an orally available multi-kinase in-
hibitor with potent activity against w.t. Raf kinases
(CRAF and BRAF) and the V600E BRAF mutant, along
the MAPK pathway, and cell surface RTKs (VEGFR-2
and VEGFR-3, PDGFR-β, c-KIT, RET, FLT-3, and, with
slightly lower potency, FGFR1) [16]. Sorafenib is FDA-
approved for the treatment of advanced renal cell carcin-
oma (RCC) [17], hepatocellular carcinoma (HCC) [18],
and differentiated thyroid cancer (DTC) [19]. In preclin-
ical studies, monotherapies or combination therapies
with sorafenib are effective against several tumors, pref-
erentially affecting CSC viability [20–23]. However, the
role of Raf-dependent and Raf-independent signaling in-
hibition in the antitumor activity of sorafenib and the
precise molecular mechanisms of its activity are still not
fully characterized [24].
In this context, we explored the activity of sorafenib
against human MPM cell cultures enriched in TICs, and
the molecular mechanisms involved. We demonstrate that
sorafenib exerts antiproliferative and proapoptotic effects,
the latter being mediated by the downregulation of Mcl-1.
Moreover, we show that sorafenib activity is mainly
dependent on the inhibition of FGFR1 signaling rather
than downstream kinases. We show that MPM TIC
cultures secreting high levels of bFGF, which induce an
autocrine/paracrine activation of FGFR1, were the most
responsive to sorafenib. Thus, it is likely that a subset of
MPM patients displaying higher FGFR1 activity could be
more sensitive to sorafenib, highlighting that accurate pa-
tients’ selection may offer the best therapeutic approach.
Methods
Chemicals
Sorafenib (US Biological) and AZ628 and PD173074
(Sigma-Aldrich) were dissolved in DMSO at 10 mM
concentration and stored at –20 °C. Drugs were diluted
with culture medium to the experimental concentrations,
with a maximum 0.1% (v/v) DMSO final concentration.
Corresponding vehicle concentrations were added to
control samples.
Cell cultures
Ten cultures (MM1–MM10) were obtained from post-
surgical specimens of human MPMs (IRCCS-AOU San
Martino-IST, Genova, Italy) upon approval of the insti-
tutional bioethics board and informed written consent
from the patients [10]. Cells were cultured in DMEM/F12
(Gibco) supplemented with 2 mM L-glutamine (Gibco),
bFGF (10 ng/ml) and EGF (20 ng/m) (Peprotech), 15 μg/
ml insulin, and 2 μg/ml heparin (Sigma-Aldrich). How-
ever, only MM1–MM4 cells showed tumorigenic activity
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in vivo and were routinely xenografted in immunodefi-
cient mice to ensure the maintenance of stemness. Cells
recovered from tumor xenografts grow as tumorspheres,
but prior to performing in-vitro experiments were allowed
to attach in plastic flask by culturing them for short
periods in medium containing 4% FBS (EuroClone). To
avoid phenotypical and biological alterations caused by
the culture conditions, all experiments were performed on
cells after very low number of in-vitro passages. Phase-
contrast images of cultures were acquired by a Nikon
TE300 microscope.
Mice xenografts
NOD-SCID mice (Charles River, Milan, Italy) aged 4–6
weeks were used to test their ability to grow in vivo. All
animal procedures were carried out under project license
in compliance with guidelines approved by the Ethical
Committee for animal use in cancer research at IRCCS-
AOU San Martino-IST (Genova, Italy) and the Italian
Ministry of Health (n° 327, Dl.vo 116/92 and 412).
Xenografts were established by pseudo-orthotopic i.p.
inoculation of MM1, MM3, and MM4 cells derived from
cultured spheres. Mice were monitored for disease
symptoms and sacrificed by CO2 asphyxiation when they
showed weight loss or any sign of suffering. Excised
tumors were divided into two parts: one part was cut
into small fragments, and a cell suspension was collected
for in-vitro testing and cultivated as already described.
The second part was cryopreserved and stored for im-
munohistochemical analysis.
Immunohistochemistry
Tumor xenograft cryo-sections were fixed in 4% PFA,
treated with 0.4% pepsin in 0.2 N HCl, 3% H2O2–PBS,
and then permeabilized and assayed for WT-1 (Dako)
expression with anti-mouse EnVision-HRP (Dako). Calre-
tinin antibody (Dako) was used on sections fixed in 4%
PFA, followed by heat-induced antigen retrieval and
treatment with 0.3% H2O2–PBS and permeabilization.
Detection was performed using streptavidin/horseradish
peroxidase (Dako). Mesothelin staining was assessed using
a secondary antibody conjugated with a green fluorescent
dye. For D2-40 staining (Dako), heat antigen retrieval was
performed using Target Retrieval Solution S1700 (Dako)
and permeabilization in PBS 10% NGS 0.3% Triton X-100.
Mouse IgG and the omission of primary antibody were
used as negative controls [25]. Digital images were cap-
tured by a Nikon Eclipse microscope (Nikon Europe).
FACS analysis
MM1, MM3, and MM4 cells, stained with specific surface
marker antibodies, conjugated with FITC or PE (BD
Biosciences) or corresponding isotype antibodies, were
analyzed using a FACScalibur (BD Biosciences), equipped
with BD CellQuest Pro software, as reported [26].
Cytotoxicity assay
Cells (3000 cells/well) were allowed to attach overnight
as already described. Sorafenib, or vehicle, was added
and cell viability was assessed after 24–72 h of treatment
using the MTT assay [27]. IC50 values were calculated
using nonlinear regression curve fit analysis with Graph
Pad Prism 5.02 [28]. Each treatment was analyzed in
quadruplicate, and the experiments were repeated at
least three times.
Apoptosis detection
Cells were treated with vehicle or sorafenib (at the con-
centration corresponding to the IC50 and 2 × IC50 values)
and stained with Annexin V-FITC and propidium iodide
(PI) (Apoptosis Detection kit; eBioscience). Samples
were analyzed by FACS. The percentage of cell death
was obtained by summing-up the percentages of early
and late apoptosis [29].
Cell cycle analysis
Control and treated cells were fixed with ethanol at 4 °C
for 1 h, and resuspended in staining solution (PBS, 20 mg/
ml RNAse A, 50 μg/ml PI, 0.5% Triton X-100; Sigma-
Aldrich). The DNA content was quantified by FACS and
the cell cycle profile analyzed by Listmode data using
ModFit™ LT software (Verity Software House) [30]. At
least 10,000 events per experimental point were collected,
gating single nuclei and excluding cell aggregates. Data
are the average of three independent experiments.
BrdU incorporation assay
Cells were seeded into 96-well plates and treated with
sorafenib for 48 h. DNA synthesis was evaluated by a
colorimetric immunoassay for the measurement of 5-
bromo-2′-deoxyuridine (BrdU) incorporation in prolifer-
ating cells (Cell proliferation ELISA; Roche), as reported
[31]. Results are expressed as percentages of the value of
untreated cells.
Western blotting
To reduce basal phosphorylation, cells were cultured for
24 h in growth factor/serum-free medium. Starved cells
were pretreated with vehicle or sorafenib for different
times (15–180 min), and then either EGF (20 ng/ml) or
bFGF (10 ng/ml) was added for 10 min. Total protein
content was measured from whole cell lysates as described
previously [32]. Equal amounts of proteins were size-
fractionated by SDS-PAGE, and transferred onto PVDF
membrane (Bio-Rad Laboratories). Blots were probed with
the following antibodies: phospho-ERK1/2 (Thr201-
Tyr204, #9101), phospho-MEK (Ser217/221, #9121),
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phospho-Akt (Ser473, #9271) phospho-STAT3 (Ser-727,
#9134), Mcl-1 (#5453), phospho-FGFR (Tyr653/654,
#3476), and FGFR1 (#9740) from Cell Signaling and α-
tubulin (#T5168; Sigma-Aldrich). Secondary mouse and
rabbit HRP-linked antibodies were from GE Healthcare.
Detection of immunocomplexes was performed using
Clarity ECL Western Blot (Bio-Rad Laboratories). All ex-
periments were repeated at least three times. Densitomet-
ric analysis of bands was performed using ChemiDoc
imaging system (Bio-Rad Laboratories).
bFGF release assay
Triplicate cell samples were seeded to obtain a semiconflu-
ent monolayer in Petri dishes and cultured in growth
factor/serum-free medium for 24 h. Thereafter, the medium
was collected and the levels of bFGF were measured using
the Quantikine ELISA (R&D Systems) according to the
manufacturer’s instructions.
Statistical analysis
All experiments were repeated at least three times. Data
from quantitative experiments are expressed as mean ±
SEM. Statistical analyses were performed by two-tailed t
test or one-way ANOVA with Tukey’s and Dunnett’s post
test, using GraphPad Prism 5.02. Statistical significance
was established at p < 0.05.
Results
Isolation and in-vitro and in-vivo expansion of TIC-enriched
cultures from human MPMs
A series of primary MPM cell cultures (MM1–MM10)
were isolated from human MPM specimens on the basis
of their ability to grow in vitro under low-serum condi-
tions. Detailed isolation procedures have been described
elsewhere [10]. All cultures were characterized for tumor
surface or stem-like marker expression, namely CD46,
CD47, CD55, CD56, CD63, CD90, and CD99 (Additional
file 1: Table S1). Among the analyzed MPM long-term
cultures, four showed tumorigenic properties when xeno-
grafted in NOD-SCID mice, suggesting that they were
enriched in the TIC subpopulation [10]; three of these
cultures (MM1, MM3, and MM4), all derived from epi-
thelioid MPMs, were selected to study the antiproliferative
effects of sorafenib due to their sustained proliferation
rate in vitro. In particular, MM1, MM3, and MM4 cul-
tures used in this study derive from cells recovered
from peritoneal tumors developed after injection in
mice, a procedure that favors the enrichment in TICs.
All the three TIC cultures develop tumor spheres when
grown under anchorage-independent culture conditions
(Fig. 1a, upper panels), but, to allow a better cellular
and biochemical evaluation, proliferation and biochem-
ical experiments were performed on short-term mono-
layer cultures obtained after disaggregation of the
spheres (Fig. 1a, lower panels). The tumorigenic ability
of MM1, MM3, and MM4 cells derived from spheroids
was checked routinely and, in order to confirm their
mesothelial phenotype and the persistence of TIC sub-
populations, cryosections of pseudo-orthotopic xeno-
grafts were analyzed for the expression of widely
recognized mesothelial markers (mesothelin, calretinin,
D2-40, and WT-1 [33, 34]) by immunohistochemistry
or immunohistofluorescence. Tumors generated from
all MPM cultures were strongly positive for calretinin,
confirming that the in-vitro growth did not modify the
epithelioid subtype phenotype of the tumor of origin,
while the expression of D2-40, WT-1, and mesothelin
supported their mesothelial origin (Fig. 1b). Similarly,
by FACS analysis, we show that in-vivo propagated cells
retain the original phenotype as far as surface markers
(i.e., high expression of CD46, CD47, CD55, CD56,
CD63, CD90, and CD99) (Fig. 1c). The expression of
stemness markers was also assessed by RT-PCR and
immunofluorescence, showing the constant expression
of BMI-1 but failing to detect the expression of SOX2,
Nanog, Oct-4, or CD133, further confirming that these
TIC-enriched cultures retain the original phenotype
profile (data not shown). These findings confirm the
enrichment in MPM TICs in the three selected cul-
tures, thus representing a reliable experimental model
to perform the study.
Sorafenib inhibits cell proliferation in human MPM TIC-
enriched cultures, in a concentration and time-dependent
manner
In-vitro antiproliferative effect of sorafenib on TIC-
enriched cultures was evaluated using increasing drug
concentrations (up to 40 μM) and analyzing cell viability
by MTT assay after 24–72 h (Fig. 2a). Sorafenib caused a
concentration-dependent reduction of cell viability, more
pronounced with increasing treatment time but, in
MM3 and MM4 cells, already evident after 24 h.
IC50 values varied among cultures: at 48 h, MM1 cells
were the most responsive to sorafenib (IC50 = 0.26 μM)
whereas MM3 and MM4 cells displayed IC50 values of
6.40 and 5.97 μM, respectively.
Similar results were obtained in BrdU incorporation ex-
periments, showing that sorafenib, used at concentrations
corresponding to the respective calculated IC50, signifi-
cantly decreased DNA synthesis in all cultures (Fig. 2b).
Sorafenib induces cell cycle arrest in G0/G1 phase in MPM
TICs
To further analyze the mechanisms mediating sorafenib
antiproliferative activity, cell cycle analysis was carried
out by FACS on PI-stained cells, treated for 48 h with
concentrations corresponding to the IC50 (Fig. 3a).
Sorafenib significantly increased the percentage of cells
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in the G1 phase in MM1 (from 58.42% ± 0.89 to 64.85 ±
2.74%, p = 0.037), MM3 (from 73.71 ± 8.78 to 88.34 ±
2.66%, p = 0.025), and MM4 (from 56.77 ± 5.68 to 69.05 ±
4.39%, p = 0.02) cultures (Fig. 3b). This effect was paralleled
by a significant decrease of the percentage of cells in the S
phase (MM1, from 26.48 ± 1.58 to 19.41 ± 1.44%, p = 0.003;
MM3, from 20.31 ± 8.4 to 6.69 ± 2.37%, p = 0.049; MM4,
from 13.41 ± 2.33 to 6.71 ± 2.66%, p = 0.009) (Fig. 3b).
These data confirmed the BrdU incorporation results and
suggest that sorafenib inhibits MPM TIC proliferation,
impairing the G1/S transition.
Sorafenib induces proapoptotic effects in MPM TICs via
Mcl-1 downregulation
The contribution of apoptosis to the antiproliferative ef-
fects of sorafenib in the TIC cultures was analyzed after
48 and 72 h of treatment. Forty-eight hours of treatment
with sorafenib, used at concentrations corresponding to
the calculated IC50 (i.e., 0.26, 6.40, and 5.97 μM for
MM1, MM2, and MM3, respectively) and 2 × IC50 (i.e.,
0.5, 13, and 12 μM, respectively) values, in MM3 and
MM4 cultures induced a statistically significant increase
in the number of apoptotic cells compared with vehicle-
treated controls that became highly significant after 72 h
(MM3, from 8.98 ± 2.8 to 17.71 ± 5.1% and 44.34 ±
10.6%; MM4, from 9.41 ± 1.6 to 13.6 ± 4.0% and 35.57 ±
13.8%) (Fig. 4a). Conversely, sorafenib-induced apoptosis
did not reach statistical significance in the highly sensi-
tive MM1 cells (Fig. 4a). We repeated these experiments
using the same concentration of sorafenib (5 μM) in all
cultures, to verify whether a higher sorafenib concentra-
tion is able induce a proapoptotic effect in MM1 cells,
b c
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Fig. 1 Characterization of TIC cultures derived from human MPMs. a Morphology of MM1, MM3, and MM4 TICs maintained in stem cell-permissive
conditions: upper panels, sphere-forming cells derived from xenografted tumors in mice and grown as nonadherent clusters (scale bar 20 μm); lower
panels, representative images of monolayers obtained by spheres (scale bar 100 μm). b Histological sections of tumors recovered from mice
xenografted with MM1, MM3, and MM4 cells stained with the indicated antibodies. Immunoreactivity was detected by immunohistochemistry and
immunofluorescence. Representative images are reported (scale bar 200 μM). c MM1, MM3, and MM4 cells, recovered from primary xenografts,
analyzed by FACS for the expression of the indicated molecules. Green, cells stained with appropriate PE or FITC-conjugated antibodies; gray, cells
incubated with PE or FITC-conjugated isotype-specific control antibody (Color figure online)
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the IC50 value of these cells being 30-fold lower than
MM3 and MM4 cells. However, the high sensitivity of
MM1 cells to sorafenib prevented this evaluation, 5 μM
being an excessively toxic concentration that resulted in
necrosis of almost all of the cells (data not shown).
Proapoptotic effects of sorafenib in MPM TICs were
associated with a strong downregulation of the anti-
apoptotic protein Mcl-1, evaluated after 24 and 48 h of
treatment (Fig. 4b). However, different levels of Mcl-1
inhibition across the cultures were observed, accord-
ingly to the different ability of sorafenib to induce
apoptosis. MM1 cells, which did not show statistically
significant proapoptotic effects at the sorafenib concen-
trations used, exhibited a significant reduction of Mcl-1
only after 48 h (–24% and –39% at concentrations cor-
responding to IC50 and 2 × IC50, respectively; p < 0.05).
MM3 and MM4 cells, showing a robust apoptotic re-
sponse to sorafenib, displayed a highly significant re-
duction of Mcl-1 expression already after 24 h of
treatment (–20% and –75% in MM3 and –18% and –34%
in MM4, at IC50 and 2 × IC50, respectively), an effect that
persisted after 48 h (Fig. 4b). Collectively, these data
suggest that sorafenib triggers apoptosis in MPM TICs by
impairing Mcl-1 expression.
Sorafenib reduces EGFR signaling in MPM TICs
Sorafenib impairs tumor growth by inhibiting multiple
kinases involved in cancer cell survival and proliferation.
Among them, it was reported that sorafenib mainly acts
by inhibiting the MAPK cascade, via the direct inhibition
of Raf kinase. To delve deeper into the intracellular
effectors mediating antiproliferative and proapoptotic
effects of sorafenib in MPM TICs, we analyzed its ability
to modulate ERK1/2, Akt, and STAT3 signaling path-
ways by western blotting (Fig. 5a). To activate these
pathways which represent the main effectors of mitogens
in MPM cells, we treated TICs with EGF or bFGF, the
growth factors commonly used to sustain in-vitro prolif-
eration of TICs [35]. Time-course experiments were per-
formed in MM cultures previously deprived of growth
factors for 24 h, treated with vehicle or sorafenib at the
IC50 values for each TIC culture for 15–180 min, and
then stimulated with EGF (20 ng/ml), for 10 min. EGF
treatment induced MEK and ERK1/2 phosphorylation in
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Fig. 2 Sorafenib impairs cell viability and proliferation in MPM primary cultures enriched in TICs. a Time and dose-dependent effects of sorafenib
on cell survival assessed by MTT assays, in MM1, MM3, and MM4 cells treated with increasing amounts of sorafenib for 24, 48, and 72 h. Each
point represents quadruplicate replicates from at least three independent experiments. Data presented as the percentage of viable cells compared
with control (vehicle-treated) cells, expressed as mean ± SEM. b Sorafenib impairs DNA synthesis in MPM TICs. Detection of proliferating cells was
evaluated by BrdU DNA incorporation in MM1, MM3, and MM4 cells cultured for 48 h in the presence and the absence of sorafenib (administered at
the respective IC50 values). Data expressed as mean % ± SD. *p <0.05, **p <0.01 vs respective controls. CTR control, BrdU 5-bromo-2′-deoxyuridine
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all MM TIC cultures (range +30/+60% over the basal);
sorafenib pretreatment reduced, but did not abolish, the
activation of these kinases (Fig. 5b). Sorafenib effects
were time dependent, and variable among the different
cultures. Maximal inhibition of ERK1/2 phosphorylation
occurred after 60 min (–58%) in MM3 cells, while in
MM4 cells the reduction of phospho-ERK1/2 (–43%)
and phospho-MEK (–52%) was observed after 180 min
(Fig. 5b). Interestingly, in MM1 cells a constitutive
activation of MEK and ERK1/2 was observed that was
further increased by EGF treatment (about +40%) but
not reduced by sorafenib (Fig. 5b).
Because Akt provides cells with a survival advantage
in the presence of apoptotic stimuli, the ability of sorafe-
nib to affect Akt signal transduction was evaluated in
EGF-treated cultures (Fig. 5a). EGF led to a significant
activation of Akt in all TIC cultures, and sorafenib tran-
siently reduced phospho-Akt levels in MM1 and MM4
cells (after 30–60 min ≈ 25–70% inhibition was detected,
but this effect vanished after 180 min) (Fig. 5b). In MM3
cells, Akt phosphorylation also observed in growth
factor-deprived control cells, was significantly increased
by EGF treatment, and was brought back to basal by
sorafenib over the time-course analysis (Fig. 5b). There-
fore, EGF-mediated MAPK signaling remained partly
active after sorafenib treatment in MM3 and MM4 cells,
and was not affected in MM1 cells. Moreover, Akt
phosphorylation induced by EGF quickly recovered from
sorafenib inhibitory effects, suggesting compensatory
activation of the phosphatidylinositol-3-kinase (PI3K)
pathway.
To further identify intracellular mediators underlying
the antiproliferative activity of sorafenib, we evaluated
the activation of the signal transducer and activator of
transcription 3 (STAT3) that mediates transcriptional
regulation of genes involved in tumor cell survival in re-
sponse to growth factors (Fig. 5a). Exposure to sorafenib
transiently reduced EGF-dependent STAT3 phosphoryl-
ation in MM1 (maximum –37% after 30 min) and MM4
(maximum –40% after 30 min) cells, whereas in MM3
cells a sustained dephosphorylation starting 30 min after
treatment (–55%) and lasting for the entire experimental
period was observed (Fig. 5b).
Taken together, these data demonstrate that, besides in-
dividual differences among MPM TICs, all three cultures
studied show, in response to sorafenib, a noncomplete in-
hibition of ERK1/2, Akt, and STAT3 pathways activated
by EGF. Moreover, it is worthy to point out that a rather
modest effect was observed on MEK activation, the direct
target of Raf.
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Sorafenib abolishes bFGF induced intracellular signaling
Signaling through the bFGF/FGFR1 plays a relevant
role in MPM proliferation [36], and thus the effects of
sorafenib on bFGF-induced intracellular pathways were
investigated. We carried out parallel time-course (15–
180 min) experiments treating growth factor-starved
MPM TICs with sorafenib at the indicated IC50 for
each culture, and then stimulated with 20 ng/ml bFGF
for 10 min (Fig. 6a). In MM3 and MM4 cells, bFGF ex-
posure caused a significant increase in MEK and ERK1/
2 activation (+45% and +35%, respectively), while in
MM1 cells a constitutive phosphorylation of MEK and
ERK1/2 was observed and not further increased by
bFGF (Fig. 6a, b). However, sorafenib abolished bFGF-
dependent activation of both MEK and ERK1/2 in all
TIC cultures (Fig. 6b), reaching a level of inhibition
significantly greater than that observed after EGF
treatment.
We also determined the effects of sorafenib on Akt
and STAT3 phosphorylation induced by bFGF as
downstream molecules involved in FGFR1-mediated
proliferation. Sorafenib abrogated Akt and STAT3
bFGF-dependent activation (up to 80%) in MM3 cells,
while the inhibition observed in MM4 was less evident,
although statistically significant at all the experimental
time points (Fig. 6b). Notably, in MM1 cells, no Akt and
STAT3 phosphorylation was observed, and therefore,
any inhibitory effect of the drug was detectable (Fig. 6a).
In their whole, these data show, in all the three
cultures, a significant higher efficacy of sorafenib in
blocking the MAPK pathway downstream to FGFR
rather than to EGFR.
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Thus, we measured the effect of sorafenib (at IC50, for
up to 60 min) on FGFR1 phosphorylation status (Fig. 7a).
We observed in MM3 and MM4 cells that the powerful
activation of the receptor upon bFGF stimulation (4-fold
increase as compared with vehicle-treated controls) was
significantly and time-dependently decreased by sorafe-
nib (about –75% after 60 min, Fig. 7b), suggesting that
FGFR1 could represent a primary target by which sorafe-
nib affects MPM TIC viability.
As expected from the reported kinase inhibition pro-
file, sorafenib did not modify EGFR phosphorylation in-
duced by EGF (data not shown).
Again MM1 cells showed a peculiar response: phospho-
FGFR1 was undetectable by western blot assay, although
total FGFR1 was present in these cells, even if at lower
levels than in MM3 and MM4 cultures (Fig. 7c). Thus we
hypothesized that the low expression of FGFR1 was
dependent on a constant activation and a very rapid
turnover of the receptor protein. This observation well-
matched the basal activation of MEK and ERK1/2 we
detected in MM1 cells (see Fig. 6a), indicative of a consti-
tutive signaling from FGFR1. Indeed, an autocrine bFGF/
FGFR activation loop controlling ERK1/2 signaling has
been identified in many cancer histotypes [37]. To verify
this hypothesis, we measured by ELISA, bFGF content in
the conditioned medium of the three TIC-enriched cul-
tures. MM1 cells released, in 24 h, more than 30–50-fold
higher levels of bFGF (304.8 ± 5.4 pg/ml) than MM3 and
MM4 cells (5.7 ± 0.30 and 9.3 ± 2.8 pg/ml, respectively)
(Fig. 7d).
Thus, high amounts of bFGF produced by MM1 cells
might lead to an autocrine constitutive activation of
FGFR1 that consequently triggers both the enhanced basal
FGFR1 signaling and the downregulation of its expression.
To further demonstrate the role of FGFR1 in MPM
TIC proliferation and its targeting by sorafenib, the
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Fig. 5 Effects of sorafenib treatment on intracellular signaling in EGF-stimulated MPM TICs. a Western blot analysis using antibodies specific to
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periods (15–180 min). Representative immunoblots of three independent experiments are reported. b Images from independent experiments
were quantified by band densitometric analysis and the resulting relative mean ratio of each protein/α-tubulin is shown. Values expressed as a
percentage of the value obtained for the EGF-stimulated cells in the same blot. Results are mean ± SEM of three experiments. *p <0.05, **p <0.01.
Dotted lines, basal (untreated) levels. EGF epidermal growth factor
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effect of the inhibition of FGFR1 activity by the small
molecule inhibitor PD173074 [38] was investigated in
growth factor-starved MM1, MM3, and MM4 cells,
cultured for 48 h in the presence of concentrations of
inhibitor ranging from 0.001 to 1 μM. A dose-dependent
reduction of cell viability, measured by MTT assay, was
indeed observed (Fig. 7e), indicating a constitutive
activation of FGFR1 that in the absence of exogenous
growth factor was likely dependent on autocrine activa-
tion by bFGF spontaneously released by the cells; more-
over, dose–response curves revealed that MM1 cells
display higher sensitivity to PD173074 (IC50 = 6.12 nM) in
agreement with the higher amount of bFGF produced by
these cells. Moreover, the inhibitory activity of PD173074
on MPM TICs was not additive with sorafenib effects
(data not shown). These results confirm that FGFR1
activation, triggered by autocrine bFGF production,
represents the major determinant for MPM TIC prolifera-
tion and the main target of the antiproliferative activity of
sorafenib.
PD173074 treatment also prevented activation of
FGFR1 downstream MAPK pathway signaling, abolish-
ing phospho-ERK1/2 levels in all the three cultures. In
particular, PD173074 was able to block both bFGF-
induced and basal/constitutive ERK1/2 phosphorylation
in MM1 cells, confirming that PD173074 prevents FGFR1-
induced ERK1/2 activation (Fig. 7f).
Because antitumor activity of sorafenib is generally
attributed to a direct inhibition of Raf, to verify the
relative contribution of the inhibition of either FGFR1 or
Raf kinase in sorafenib modulation of MEK/ERK signaling
we used the pan-Raf kinase inhibitor AZ628, which also
inhibits several tyrosine protein kinases like sorafenib.
Western blot experiments in MM1 cells treated with
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AZ628 (0.1, 1, and 10 μM) showed a significant and
concentration-dependent inhibition of MEK phosphoryl-
ation, the direct Raf target (around –60% at 1 and 10 μM)
and its downstream substrate ERK1/2 (–49% at 10 μM)
after EGF stimulation (Fig. 8a). Thus, in MM1 cells in
which sorafenib fails to suppress the EGF-dependent acti-
vation of MEK and ERK1/2, AZ628 efficiently impaired
the signaling cascade from Raf to MEK and, consequently,
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to ERK1/2. Moreover, as expected, the sustained EGF-
dependent phosphorylation of MEK and ERK1/2 in the
sorafenib-responsive MM4 culture was also significantly
suppressed (–70 and –80%, respectively) by exposure to
AZ628 (Fig. 8b). Overall these results suggest that bFGF-
driven signaling plays a relevant role in the proliferation of
MPM TICs and that cytotoxic and proapoptotic effects
of sorafenib are mainly exerted by the direct inhibition
of FGFR1, while the modulation of Raf activity seems
less relevant (Fig. 9).
Discussion
Despite the availability of multiple drug regimens, the sur-
vival rate of MPM patients is dramatically poor [3]. The
identification of novel therapeutic approaches requires the
development of preclinical in-vitro cellular models able to
identify drugs with high probability to be efficacious in the
clinic. Continuous cancer cell lines are commonly used as
representative models of a given tumor histotype, but their
translational value is often low. In solid and hematologic
tumors, the presence of TIC/CSC subpopulations is at the
basis of cellular heterogeneity. TICs have different pheno-
type and drug sensitivity than the bulk of tumor cells,
more closely resembling cognate tumor profiles than com-
monly used cell lines, causing inter-tumor and intra-
tumor variability not reproducible in established cell lines.
In this respect, MPM TICs in vitro retain patient-specific
traits and, due to the relatively short time required to ob-
tain their enrichment in primary cultures, the genotypic
and phenotypic modifications induced by in-vitro growth
are minimized [39]. Hence, TIC cultures, although they
pose several technical challenges, better reproduce the ori-
ginal tumor features than long-term established cell lines,
in particular regarding drug responsiveness.
In this study, we used three individual MPM TIC cul-
tures representing a suitable model to improve the value
of studies in preclinical research. The number of patient-
derived cultures we analyzed is not high due to the diffi-
culties to obtain postsurgical samples and to establish
primary mesothelioma stem cell-enriched cultures (only
four of 10 cultures analyzed retained in-vivo tumorigen-
icity). Notwithstanding, we believe that this experimental
model is highly representative of the MPM phenotype and
its biological behavior, and is extremely useful to evaluate
the effects of sorafenib on cell viability and the mecha-
nisms involved.
Sorafenib is reported to exert antitumor effects via
both the direct blockade of Raf in the ERK1/2 pathway
and the inhibition of multiple RTKs. However, the pre-
cise pharmacological mechanisms responsible for its ef-
fects are still controversial and why sorafenib is not
always effective in patients remains poorly understood
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[24]. Since sorafenib approval for RCC [17], HCC [18],
and DTC [19], several clinical studies have investigated
the effectiveness sorafenib in other tumors [40]. How-
ever, likely due to the molecular heterogeneity of these
tumors, only few patients showed transient benefit from
these trials, while disease progression occurred in most of
the patients; therefore, determinants of clinical efficacy of
sorafenib need confirmatory challenge. Analogously, after
a phase I study which determined safety, pharmacokinet-
ics, and efficacy of sorafenib in combination with doxo-
rubicin in MPM patients [41], two phase II trials reported
limited activity [42, 43]. The modest outcome of sorafenib
as monotherapy in advanced MPM patients, although
similar to that seen with other VEGFR TKIs [42], might
be due to different factors, including the lack of MPM
patient selection as a consequence of the absence of pre-
dictive markers for drug response. In particular, the identi-
fication of molecular mechanisms crucial for tumor cell
proliferation affected by sorafenib and, possibly, ensuring
drug synergism with cytotoxic drugs should be considered
to identify potentially responsive patient subgroups. Over-
all, low number of patients entered the cited clinical trials,
and the treatment of a molecularly undefined group of
MPM patients concurs with disappointing in-vivo effect-
iveness of sorafenib, making their clinical significance
uncertain. Moreover, because MPMs are not exclusively
driven by gene mutation and amplification or RTK activa-
tion, and because intracellular pathways and autocrine/
paracrine loops coexist and may interact with RTK func-
tions, further molecular investigation and patient selection
are warranted.
In this context, patient-derived TIC cultures may rep-
resent a novel preclinical model with higher translational
predictivity, able to identify a subset of patients whose
tumors show molecular characteristics predictive for
positive clinical responses.
Previous in-vitro studies provided evidence that sorafe-
nib targets TICs isolated from cell lines [44] and primary
cultures [20] in other tumor types. Here we demonstrate
that sorafenib also impairs MPM TIC viability, mainly via
the inhibition of FGFR1 activity rather than downstream
molecules.
Sorafenib effects occur in the nanomolar/low micro-
molar range in all the TIC cultures analyzed, showing
similar sensitivity profiles and IC50 values to MPM cell
lines [12, 45]. These data are in accordance with most
studies reporting the cytotoxic effect in the 1–10 μM
range of sorafenib in human cancer cell lines from
different tumor types [46]. Efficacious sorafenib plasma
concentrations achievable in patients are usually reported
within the nanomolar range, although in some case
concentrations within the micromolar range were reached
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Fig. 9 Diagram depicting the proposed mechanism of action of sorafenib in mesothelioma TICs. Sorafenib treatment causes the inhibition of
MEK and ERK1/2 phosphorylation and the downregulation of Mcl-1 expression, leading to cell cycle arrest and activation of the apoptotic program.
Sorafenib antitumor effects are mainly ascribed to a direct inhibition of FGFR1 activity rather than downstream effectors, such as Raf/Ras/MEK/ERK
pathway. Thus TIC cultures autocrinally activating FGFR1 via the release of high amount of bFGF are likely to be more sensitive to the drug. bFGF basic
fibroblast growth factor, FGFR FGF receptor, TIC tumor-initiating cell
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[47], which are similar to the sorafenib concentrations
effective in our cell model. Moreover, the concentrations
at which sorafenib inhibits FGFR1 autocrine activation in
MPM TICs are similar to those reported to affect the
RAF/MEK/ERK pathway and activated RTK in human
breast cancer cell lines [48]. Notwithstanding all these
considerations, we have to acknowledge that the require-
ment of high sorafenib concentration to affect MPM TIC
viability in vitro is still an issue when preclinical results
have to be translated to the clinical setting, because kinase
inhibitors are often associated with nonspecific dose-
dependent toxic effects.
In this context, our results showing a nonhomogeneous
sensitivity to the drug among TIC cultures isolated from
different tumors suggest that distinctive molecular fea-
tures determine the efficacy of the treatment. In particular,
we show that TICs isolated from a human MPM (MM1)
are highly responsive to sorafenib (IC50 = 260 nM) due to
a constitutive autocrine activation of FGFR1, which we
identified as the main molecular target in these cells, as
discussed in the following. If this observation was to be
confirmed in different patient-derived cultures, we can
hypothesize that the identification of autocrine activation
of this receptor could represent a starting point to identify
subgroup of patients likely to be highly responsive to
sorafenib.
As far as the mechanisms of action in MPM TICs,
sorafenib treatment for 24–48 h induces G1 cell cycle
arrest, as also reported in NSCLC [49] or thyroid cancer
cell lines [50]. Interestingly, in our experimental model,
cell death was mostly observed after 72 h of treatment,
indicating that sorafenib inhibition of MPM TIC prolif-
eration precedes the activation of the apoptotic process.
Sorafenib-induced apoptosis was observed in MM3 and
MM4 cultures, while apoptotic cell death, although
present, was less relevant in MM1 cells using sorafenib
at concentrations corresponding to the IC50. Cytotoxic
activity of sorafenib in human cancer cells has been
ascribed to downregulation of anti-apoptotic proteins as
Mcl-1 [20, 51]; accordingly, we observed that sorafenib
downregulates the expression of Mcl-1 in all the three
MPM TIC cultures, an event contributing to the proa-
poptotic activity of this drug.
Ras/Raf/MEK/ERK and PI3K/Akt are the main signal
transduction cascades involved in MPM development and
progression, and in TIC proliferation and survival, while
STAT3 contributes to maintain the transformed state and
to promote metastasis [52]. To delve deeper into the mo-
lecular mechanisms mediating sorafenib activity, we tested
its effects on MPM TICs in the presence of either EGF or
bFGF. EGF is relevant for MPM pathogenesis and prolifer-
ation [12, 35, 52]. In MM3 and MM4 cells, sorafenib
slightly attenuates EGF-dependent MEK, ERK1/2, and
STAT3 phosphorylation, while Akt activation is transiently
inhibited. Even if the extent of inhibition differs among
MM1, MM3, and MM4 cells, sorafenib caused an incom-
plete reduction of EGF effects in all the cultures analyzed.
On their whole, these findings suggest that sorafenib-
mediated inhibition of EGF-dependent MAPK signaling
via Raf inhibition is not fully efficient in MPM TICs,
and elevated levels of phosphorylated MEK and ERK1/2
are maintained even when Raf activity is theoretically
completely blocked by sorafenib. To analyze the regula-
tion of Raf/MEK/ERK signaling and to exclude that
functional alterations and/or mutations in the MAPK
pathway were responsible for the weak response to so-
rafenib, we used the pan-Raf inhibitor AZ628. AZ628
significantly inhibited EGF-dependent MEK and ERK1/
2 phosphorylation in the sorafenib-responsive MM4
TICs. These results suggest that modulation of the
MAPK pathway is readily achievable in MPM TICs and
the low sorafenib efficacy is not due to intrinsic mecha-
nisms of Raf activation. Thus, the direct inhibition of
Raf seems to play a minor role in the antiproliferative
activity of sorafenib in MPM TICs.
Because overexpression of alternative growth factors
has been proposed as an escape mechanism from
targeted therapies [53], we evaluated the activity of
sorafenib in TICs stimulated with bFGF. Interestingly,
sorafenib caused an almost complete abolishment of
bFGF-induced phosphorylation of both MEK and ERK1/2.
Akt and STAT3 activation by bFGF was also inhibited.
The differential ability of sorafenib to inhibit MAPK cas-
cade activated by bFGF and EGF is highly suggestive that
sorafenib effects in MPM TICs have to be mainly ascribed
to a direct inhibition of FGFR tyrosine kinase, rather than
downstream effectors such as Raf. This evidence is further
confirmed by the demonstration that sorafenib directly
abrogates ligand-dependent FGFR1 (but not EGFR)
phosphorylation.
Thus, we propose that FGFR1 is a major target of the
antiproliferative activity of sorafenib in MPM TICs. The
FGFR family, and FGFR1 in particular, is highly expressed
in MPM cell lines [54], and represents an emerging thera-
peutic target for cancer treatment [55]. In several tumors,
FGFR signaling drives tumorigenesis being activated by
autocrine/paracrine loops [56]. For example, an aberrant
autocrine bFGF circuit is a key component of downstream
ERK1/2 activation and tumor aggressiveness in NSLC
[57], breast cancer [58], head and neck squamous cell car-
cinoma [59], and mesothelioma [36] cells, and mediates
resistance to RTK inhibitors [60]. Our data support that
FGFR-driven signaling plays a relevant role in the biology
of MPM TICs and that sorafenib cytotoxic and proapop-
totic effects are mainly ascribed to inhibition of FGFR1 ra-
ther than a Raf-dependent mechanism. These data, quite
unexpectedly, contrast to what is commonly observed in
other tumor types in which sorafenib mainly acts through
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a direct inhibition of Raf kinase. Conversely, in the MPM
TICs we analyzed, sorafenib was much more potent on
FGFR1 than on RAF, although the latter kinase is active
and functional, as shown by the efficient inhibition
induced by the selective inhibitor AZ628. Importantly,
sorafenib activity on receptor downstream signaling is
commonly considered a key feature of this drug to inter-
fere with different RTK activity. We show that, at least in
MPM TICs, this does not occur and a direct effect on
FGFR1 is mediating the antitumor efficacy of sorafenib.
Actually, the mechanism of action of sorafenib in all three
TIC cultures converges on FGFR1, this receptor being in-
strumental for the response to the drug of all the cultures
analyzed (MM1, MM3, and MM4).
Indeed, the observation that sorafenib effects in all TICs
are mainly mediated by the direct inhibition of FGFR1 ac-
tivity can also explain the higher sensitivity of MM1 cells
in comparison with MM3 and MM4 cells, as regards the
antiproliferative activity of sorafenib (IC50: 0.26 μM in
MM1 vs 6.40 and 5.97 μM in MM3 and MM4). In fact,
MM1 cells display a constitutive activation of the MAPK
pathway mainly dependent on the autocrine activation of
FGFR1; in fact, untreated MM1 cells release high levels of
bFGF, reaching concentrations about 30-fold higher than
those of MM3 and MM4 cells. Thus, FGFR1 constitutive
activity likely represents the main stimulus to MM1 cell
proliferation and, consequently, being the key target of so-
rafenib effects, could determine the higher sensitivity of
these cells. Notably, in MM1 cells, the release of large
amounts of bFGF also caused an ultra-rapid turnover of
FGFR1 activated form, likely sustained by the ligand auto-
crine loop, resulting in undetectable levels of receptor
autophosphorylation even after bFGF exposure by western
blot analysis, as described previously [61].
The FGFR1 activation/inactivation cycle is thus possibly
boosted in cells with a strong bFGF production, although
maintaining a sufficient amount of free receptor for bind-
ing, as reported [62], and also observed for chemokine re-
ceptors in human glioblastoma TICs [63].
Taken together, these data support that FGFR-driven
signaling plays a relevant role in the proliferation and
survival of MPM TICs and represents a common and
determining factor mediating sorafenib antiproliferative
affects, in all three cultures analyzed. Moreover, the
level of bFGF secretion and autocrine activation of
FGFR1 significantly impacts the entity of the antiprolif-
erative response to the drug. Importantly, these data
also highlight a pivotal Raf-independent mechanism
underlying the cytotoxic and proapoptotic effects of so-
rafenib is evident in MPM TICs, in contrast with a dir-
ect inhibition of Raf proposed in different tumors. In
particular, to the best of our knowledge, this is the first
study demonstrating the relationship between bFGF
production from tumor cells and the susceptibility to
sorafenib of a TIC subpopulation. The translation of
these results into a clinical setting could provide indica-
tions to select MPM patients likely responsive to treat-
ment with sorafenib. The possibility of bFGF-driven
proliferation and survival of tumor cells via autocrinally
regulated pathways may be crucial to screen potentially
responsive patients to targeted therapies, like sorafenib
[64]. In fact, clinical trials testing unselected patients
did not report a significant efficacy of the drug [42, 43].
Thus, we propose that the tumor dependence on bFGF
and the high efficacy of sorafenib in inhibiting the
FGFR axis might help with predicting tumor respon-
siveness to sorafenib.
Conclusions
We report that sorafenib is a powerful inhibitor of
MPM TIC proliferation and survival, mainly acting on
FGFR1, whose level of activation directly correlates
with drug efficacy and potency (Fig. 9). This distinctive
mechanism may allow the selection of patient subsets
in whom autocrine bFGF activation loops are active
and who are more likely to better respond to sorafenib
monotherapy or to association with drugs targeting al-
ternative/converging Raf-dependent and independent
intracellular pathways.
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